Compare Stocks: IMDX, INDP, PBYI, and KMDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMDX Oncocyte	$3.44 -0.9%	$4.20	$2.42 ▼ $8.51	$113.55M	1.8	288,502 shs	402,991 shs
INDP Indaptus Therapeutics	$2.38 +12.3%	$1.94	$0.92 ▼ $5.96	$282.47M	0.97	1.59 million shs	567,914 shs
KMDA Kamada	$8.31 +1.3%	$8.01	$6.50 ▼ $9.35	$471.54M	0.89	133,086 shs	57,867 shs
PBYI Puma Biotechnology	$9.51 -3.4%	$9.07	$4.57 ▼ $10.10	$507.94M	1.22	297,013 shs	454,750 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMDX Oncocyte	-0.86%	-12.24%	-14.21%	-40.07%	+343,999,900.00%
INDP Indaptus Therapeutics	+12.26%	-38.18%	+103.42%	-21.45%	-32.00%
KMDA Kamada	+1.34%	-4.70%	-1.07%	+10.80%	+21.49%
PBYI Puma Biotechnology	-3.35%	-2.66%	-1.86%	+15.13%	+80.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMDX Oncocyte	$3.44 -0.9%	$4.20	$2.42 ▼ $8.51	$113.55M	1.8	288,502 shs	402,991 shs
INDP Indaptus Therapeutics	$2.38 +12.3%	$1.94	$0.92 ▼ $5.96	$282.47M	0.97	1.59 million shs	567,914 shs
KMDA Kamada	$8.31 +1.3%	$8.01	$6.50 ▼ $9.35	$471.54M	0.89	133,086 shs	57,867 shs
PBYI Puma Biotechnology	$9.51 -3.4%	$9.07	$4.57 ▼ $10.10	$507.94M	1.22	297,013 shs	454,750 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMDX Oncocyte	-0.86%	-12.24%	-14.21%	-40.07%	+343,999,900.00%
INDP Indaptus Therapeutics	+12.26%	-38.18%	+103.42%	-21.45%	-32.00%
KMDA Kamada	+1.34%	-4.70%	-1.07%	+10.80%	+21.49%
PBYI Puma Biotechnology	-3.35%	-2.66%	-1.86%	+15.13%	+80.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMDX Oncocyte	2.33	Hold	$10.50	205.23% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
KMDA Kamada	3.00	Buy	$13.50	62.45% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-36.91% Downside

Current Analyst Ratings Breakdown

Latest IMDX, INDP, PBYI, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
9/21/2026	IMDX Oncocyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	IMDX Oncocyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMDX Oncocyte	$4.05M	27.79	N/A	N/A	($1.10) per share	-3.13
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
KMDA Kamada	$180.46M	2.65	$0.62 per share	13.43	$4.68 per share	1.78
PBYI Puma Biotechnology	$228.40M	2.15	$0.81 per share	11.80	$2.59 per share	3.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMDX Oncocyte	-$50.22M	-$1.49	N/A	N/A	N/A	-2,955.63%	N/A	-107.52%	N/A
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	21.87	14.33	0.69	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	18.29	67.93	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)

Latest IMDX, INDP, PBYI, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/10/2026	Q2 2026	IMDX Oncocyte	N/A	-$0.23	N/A	-$0.31	N/A	$0.24 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMDX Oncocyte	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.56%	N/A	34.21%	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest IMDX, INDP, PBYI, and KMDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMDX Oncocyte	N/A	2.00	1.98
INDP Indaptus Therapeutics	N/A	19.49	19.49
KMDA Kamada	N/A	4.06	2.29
PBYI Puma Biotechnology	N/A	2.91	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMDX Oncocyte	55.35%
INDP Indaptus Therapeutics	7.06%
KMDA Kamada	20.38%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
IMDX Oncocyte	2.21%
INDP Indaptus Therapeutics	9.94%
KMDA Kamada	36.10%
PBYI Puma Biotechnology	22.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMDX Oncocyte	58	32.72 million	32.00 million	N/A
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
PBYI Puma Biotechnology	179	51.62 million	40.16 million	Optionable

IMDX, INDP, PBYI, and KMDA Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Sets New 1-Year High - Should You Buy?

September 30 at 12:39 PM | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Trading Up 5.8% - Here's Why

September 24, 2026 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Reaches New 52-Week High - Should You Buy?

September 24, 2026 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Hits New 12-Month High - Here's What Happened

September 22, 2026 | marketbeat.com

Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 18, 2026 | marketscreener.comM

Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer

September 18, 2026 | tipranks.com

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

September 18, 2026 | zacks.com

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 17, 2026 | businesswire.com

Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $45,500.00 in Stock

September 17, 2026 | insidertrades.com

Troy Edward Wilson Sells 5,000 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

September 16, 2026 | marketbeat.com

Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $566,808.00 in Stock

September 16, 2026 | marketbeat.com

Wellington Management Group LLP Invests $1.02 Million in Puma Biotechnology, Inc. $PBYI

September 12, 2026 | marketbeat.com

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

September 9, 2026 | finance.yahoo.com

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

September 8, 2026 | seekingalpha.com

Bank of New York Mellon Corp Takes $2.93 Million Position in Puma Biotechnology, Inc. $PBYI

September 7, 2026 | marketbeat.com

220,316 Shares in Puma Biotechnology, Inc. $PBYI Purchased by Empowered Funds LLC

September 4, 2026 | marketbeat.com

Zacks Research Has Positive Outlook of PBYI FY2026 Earnings

September 3, 2026 | marketbeat.com

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

August 12, 2026 | zacks.com

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

August 7, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, INDP, PBYI, and KMDA Company Descriptions

Oncocyte NASDAQ:IMDX

$3.44 -0.03 (-0.86%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.52 +0.08 (+2.18%)

As of 10/2/2026 07:30 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Indaptus Therapeutics NASDAQ:INDP

$2.38 +0.26 (+12.26%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.36 -0.02 (-0.92%)

As of 10/2/2026 07:30 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Kamada NASDAQ:KMDA

$8.31 +0.11 (+1.34%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.30 -0.02 (-0.18%)

As of 10/2/2026 07:30 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Puma Biotechnology NASDAQ:PBYI

$9.51 -0.33 (-3.35%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.39 -0.12 (-1.26%)

As of 10/2/2026 07:30 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMDX, INDP, PBYI, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMDX, INDP, PBYI, and KMDA Earnings

Compare Dividends

Latest IMDX, INDP, PBYI, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMDX, INDP, PBYI, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, INDP, PBYI, and KMDA Company Descriptions

Oncocyte NASDAQ:IMDX

Indaptus Therapeutics NASDAQ:INDP

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMDX, INDP, PBYI, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMDX, INDP, PBYI, and KMDA Earnings

Compare Dividends

Latest IMDX, INDP, PBYI, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMDX, INDP, PBYI, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, INDP, PBYI, and KMDA Company Descriptions

Oncocyte NASDAQ:IMDX

Indaptus Therapeutics NASDAQ:INDP

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools